Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

CyberKnife radiosurgery is a 15-minute outpatient procedure that requires no anesthesia or hospital admission, offering a non ...

Veterans diagnosed with post-traumatic stress disorder may experience thrashing sleep, which can lead to more extensive ...

A woman who is at least the fourth generation of her family to suffer a "cruel" brain disorder, which leaves people trapped ...

Neurodiagnostics Market Research Report In 2020, the global neurodiagnostics market was valued at $6,530 million and is projected to reach ...

This advanced platform utilizes focused ultrasound guided by MRI to precisely target and ... disorders such as essential tremor and Parkinson’s disease. (Mike Stocker/South Florida Sun Sentinel ...

This advanced platform utilizes focused ultrasound guided by MRI to precisely target and ... as essential tremor and tremor-dominant Parkinson’s disease. The machine can stop the involuntary ...